Personalis (NASDAQ:PSNL) CEO Christopher Hall Sells 100,000 Shares

Personalis, Inc. (NASDAQ:PSNL – Get Free Report) CEO Christopher Hall sold 100,000 shares of the company’s stock in a transaction that occurred on Friday, June 26th. The shares were sold at an average price of $13.15, for a total transaction of $1,315,000.00. Following the completion of the transaction, the chief executive officer owned 235,986 shares in the company, valued at approximately $3,103,215.90. This represents a 29.76% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Personalis Stock Up 3.4%

PSNL stock opened at $13.02 on Friday. The company has a 50 day moving average of $8.42 and a two-hundred day moving average of $8.29. The company has a market cap of $1.36 billion, a price-to-earnings ratio of -12.76 and a beta of 2.28. Personalis, Inc. has a 12-month low of $3.84 and a 12-month high of $13.37.

Get Personalis alerts:

Personalis (NASDAQ:PSNL – Get Free Report) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.29) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.06). Personalis had a negative return on equity of 43.52% and a negative net margin of 148.11%.The company had revenue of $15.47 million during the quarter, compared to analyst estimates of $14.48 million. On average, research analysts anticipate that Personalis, Inc. will post -1.06 EPS for the current year.

Hedge Funds Weigh In On Personalis

Several hedge funds have recently bought and sold shares of PSNL. T. Rowe Price Investment Management Inc. raised its holdings in Personalis by 273.9% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 10,780,290 shares of the company’s stock valued at $85,812,000 after buying an additional 7,896,714 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its stake in shares of Personalis by 1,332.2% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,448,585 shares of the company’s stock worth $11,531,000 after acquiring an additional 1,347,439 shares in the last quarter. Kennedy Capital Management LLC increased its holdings in shares of Personalis by 196.2% during the 3rd quarter. Kennedy Capital Management LLC now owns 1,935,078 shares of the company’s stock valued at $12,617,000 after acquiring an additional 1,281,695 shares during the last quarter. Aberdeen Group plc increased its holdings in shares of Personalis by 36.1% during the 4th quarter. Aberdeen Group plc now owns 3,249,895 shares of the company’s stock valued at $25,869,000 after acquiring an additional 861,948 shares during the last quarter. Finally, ARK Investment Management LLC raised its stake in shares of Personalis by 11.3% in the 3rd quarter. ARK Investment Management LLC now owns 7,910,191 shares of the company’s stock valued at $51,574,000 after acquiring an additional 802,268 shares in the last quarter. 61.91% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on PSNL. BTIG Research dropped their target price on Personalis from $13.00 to $11.00 and set a “buy” rating on the stock in a research report on Monday, May 11th. Needham & Company LLC lifted their price target on Personalis from $10.00 to $12.00 and gave the company a “buy” rating in a report on Friday, February 27th. Weiss Ratings reissued a “sell (d-)” rating on shares of Personalis in a research note on Tuesday, April 21st. Wall Street Zen downgraded Personalis from a “hold” rating to a “sell” rating in a report on Saturday, June 13th. Finally, Morgan Stanley cut their price objective on shares of Personalis from $10.00 to $9.00 and set an “equal weight” rating on the stock in a research report on Tuesday, May 12th. Five analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Personalis has an average rating of “Moderate Buy” and a consensus target price of $11.00.

View Our Latest Analysis on Personalis

About Personalis

(Get Free Report)

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.

Featured Stories

• Five stocks we like better than Personalis
• Rocket Lab’s NASA Win Tests Key Support After Sharp Pullback
• AST SpaceMobile Just Nailed a Major Launch—So Why Is the Stock Crashing?
• Palantir’s Valuation Problem Just Met 2 New Growth Catalysts
• Xcel Energy Stock Offers Stability as Electricity Demand Builds

Receive News & Ratings for Personalis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Personalis and related companies with MarketBeat.com's FREE daily email newsletter.